Bayer Aktiengesellschaft (SWX:BAYN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 43.22B +67.8% |
| Revenue (ttm) | 41.89B -1.7% |
| Net Income | -1.60B |
| EPS | -1.63 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 10.38 |
| Dividend | 0.10 (0.23%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 5 |
| Open | 44.18 |
| Previous Close | 47.36 |
| Day's Range | 44.18 - 44.18 |
| 52-Week Range | 32.75 - 48.69 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Bayer Aktiengesellschaft Quarterly report: Q2 2026
Bayer Aktiengesellschaft has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bayer Aktiengesellschaft Slides: Q2 2026
Bayer Aktiengesellschaft has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Bayer Aktiengesellschaft Earnings release: Q2 2026
Bayer Aktiengesellschaft released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bayer Aktiengesellschaft Q2 Earnings Call Highlights
Bayer Aktiengesellschaft ETR: BAYN said first-half sales rose 3% on a currency- and portfolio-adjusted basis to €24.3 billion, as growth in Crop Science and Consumer Health offset pressure in parts of...
Bayer Aktiengesellschaft Earnings Call Transcript: Q2 2026
Sales grew 3% to EUR 24.3 billion in H1 2026, with margin expansion in Crop Science and resilience in Pharma. Litigation progress, a EUR 3 billion Apollo investment, and $5 billion in bonds strengthened the balance sheet. Full-year guidance was reiterated.
Bayer Aktiengesellschaft Quarterly report: Q2 2026
Bayer Aktiengesellschaft has published its Q2 2026 quarterly earnings report on August 4, 2026.
Bayer Aktiengesellschaft Earnings release: Q2 2026
Bayer Aktiengesellschaft released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Bayer Returns To Q2 Profit, Sales Edge Up; Confirms Outlook
LEVERKUSEN (dpa-AFX) - German pharmaceutical and biotechnology company Bayer AG (BYR.L) returned to profit in the second quarter, primarily helped by significantly lower other operating expenses.N...
Bayer Swings to Net Profit on Smaller Litigation Charges
The company said its 2026 sales and earnings forecasts were unchanged when adjusted for currency changes, and that year-end net debt would be lower than originally projected.
Agentic Marketers: Bayer, Zoom, and More Reveal Their Biggest AI Wins
Learn how the top marketers from Bayer, Zoom, and a health tech firm have implemented AI over the past month, and what they hope to accomplish over the next quarter.
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
Bayer: New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
New research by Economist Enterprise, supported by Bayer, highlights the potential of self-care to become a more integrated component of modern health systems The research underscores that self-ca...
New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters
LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched...
KAPA Forms Strategic Partnership with Bayer for Innovative Cancer Treatment
KAPA Forms Strategic Partnership with Bayer for Innovative Cancer Treatment
Kairos Pharma announces collaboration with Bayer to enhance XOFIGO
Kairos Pharma (KAPA) announced a strategic collaboration with Bayer (BAYRY) to evaluate Kairos Pharma’s lead antibody ENV-105, a first-in-class CD105/BMP signaling inhibitor, in combination with Bayer...
Bayer, Henry Ford Health partner to expand access to clinical trials
Bayer (BAYRY) and Henry Ford Health announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry...
Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials
DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings toge...
Sabanto announces oversubscribed Series B funding led by Leaps by Bayer
Sabanto announced an oversubscribed Series B funding led by Leaps by Bayer (BAYRY) with participation by Sustainable Forward Capital, InnoVenture Iowa, Fulcrum Global Capital, DCVC, and Yara. The roun...
Pesticide makers stack wins against US environmental, public health groups
The U.S. Supreme Court handed a major legal victory to German agrichemical and pharmaceutical company Bayer last month when it reined in thousands of lawsuits accusing the German company of failing to...
Apollo to Acquire Stake in Bayer's Long-Acting Contraceptive Business for â¬3 Billion
Apollo to Acquire Stake in Bayer's Long-Acting Contraceptive Business for â¬3 Billion
Bayer (BAYRY) Secures â¬3B Equity Investment to Strengthen Capital Structure
Bayer (BAYRY) Secures â¬3B Equity Investment to Strengthen Capital Structure
Bayer secures EUR 3B to improve capital structure
Bayer (BAYRY) has secured EUR 3B in equity capital to improve its capital structure. The company signed a respective agreement with the global asset management firm Apollo (APO) on Friday.
Bayer Sells $3.4 Billion Contraceptives Stake to Apollo
Bayer AG sold a minority stake in its contraceptives business to Apollo Global Management Inc. for €3 billion ($3.4 billion) and will use the funds raised to help cover its ballooning litigation costs...
Apollo to Buy $3.4 Billion Stake in Bayer Contraceptives Business
The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.
Bayer gets €3 billion in Apollo deal for contraceptives unit
Bayer said on Friday it had secured €3 billion ($3.4 billion) in equity from Apollo-managed funds in a deal tied to its long-acting reversible contraceptives, or LARC, business, aiming to bolster i...